GenScript Launches Custom Rabbit Monoclonal Antibody Service
Now, One of Two Major Companies Offering Difficult-To-Hybridize Rabbit mAbs
Piscataway, NJ, June 27, 2017 (Newswire.com) - GenScript announced the launch of its new custom rabbit monoclonal antibody (mAb) service MonoRabTM, as part of the integrated premium antibody service portfolio.
Rabbit monoclonal antibodies (mAbs) are well known for their high affinity, specificity, diversity, and their ability to recognize hidden, hard-to-target epitopes. They are ideal for anti-idotypic (anti-ID) antibodies, PK, and immunogenicity studies, and in vitro diagnostics (IVD) assays/kit development.
“It is a challenge to obtain stable hybridoma clones to produce rabbit mAbs. Until now, researchers’ access to this important technology has been limited,” said Dr. Liusong Yin, Head of Antibody Department at GenScript. “Our proprietary MonoRab™ technology uses a combination of hybridoma technologies and early-stage monoclonal antibody sequencing to deliver custom rabbit mAbs that are more specific with higher affinity and diversified to meet the requirements for a growing range of applications. The delivered rabbit antibody sequences are stable forever and by choosing recombinant expression, GenScript clients can benefit from better antibody reproducibility, validation, and IP protection.”
"Until now, researchers' access to this important technology has been limited. Our proprietary MonoRab™ technology uses a combination of hybridoma technologies and early-stage monoclonal antibody sequencing to deliver custom rabbit mAbs that are more specific with higher affinity and diversified to meet the requirements for a growing range of applications."
GenScript is one of the two major companies in the world able to deliver custom rabbit mAbs for commercial purpose. MonoRab™ can be used to develop rabbit mAbs against challenging targets, including anti-ID antibodies, membrane receptors, nanobodies, small molecule compounds, epigenetic modifications, and antibody drugs.
Since 2004, GenScript’s comprehensive antibody services have produced more than 14,000 custom monoclonal antibodies and more than 100,000 polyclonal antibodies. As a “One-Stop Solution” to make research easier, GenScript’s diverse monoclonal antibody service portfolio includes premium hybridoma lead generation, high-throughput screening (including FACS), antibody sequencing, antibody humanization and affinity maturation, recombinant antibody expression, and high-throughput gene-to-antibody production. For more information on GenScript's MonoRab™ click here. For more information on GenScript’s complete portfolio of antibody services, click here.
About GenScript - GenScript is the world leader in gene synthesis, and a peptide, protein, and antibody research partner for fundamental life science research, translational biomedical research, early stage biopharmaceutical development, and synthetic biology. Since its founding in 2002, GenScript has provided services and products to scientists in more than 100 countries worldwide. The company delivers biological research services encompassing gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, in vitro and in vivo pharmacology and industrial synthetic biology products. For more information, visit www.genscript.com.
Forward-Looking Statement Disclaimer: This press release contains forward-looking statements, including, without limitation, statements related to the earnings and sales forecasts. These forward-looking statements are based upon GenScript’s current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: market condition, global stability, new technologies. The forward-looking statements made in this press release speak only as of the date of this press release. GenScript expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in GenScript’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
For More Information: